Factorial design optimization of micelle enhanced synchronous spectrofluorimetric assay of Omarigliptin: Applied to content uniformity testing and in vitro drug release

被引:11
|
作者
Ayoub, Bassam M. [1 ,2 ]
Mowaka, Shereen [1 ,2 ,3 ]
Arafa, Mona G. [2 ,4 ,5 ]
机构
[1] BUE, Fac Pharm, Pharmaceut Chem Dept, Cairo 11837, Egypt
[2] BUE, Fac Pharm, CDRD, Cairo, Egypt
[3] Helwan Univ, Fac Pharm, Analyt Chem Dept, Cairo, Egypt
[4] BUE, Fac Pharm, Pharmaceut Dept, Cairo, Egypt
[5] Mansoura Univ Hosp, Chemotheraput Unit, Mansoura, Egypt
关键词
factorial design optimization; micelle enhanced spectrofluorimetry; Omarigliptin; pharmaceutical analysis; Plackett-Burman factorial design; synchronous spectrofluorimetry; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; HANTZSCH CONDENSATION REACTION; TYPE-2; DIABETES-MELLITUS; WEEKLY DPP-4 INHIBITOR; ONCE-WEEKLY TREATMENT; HUMAN PLASMA; FLUORESCENCE; HYDROCHLORIDE; TABLETS; STABILITY;
D O I
10.1002/bio.3479
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A micelle enhanced spectrofluorimetric method was developed for determination of Omarigliptin (OMG) based on its native fluorescence behavior. The interaction of OMG with surfactants and macromolecules was studied. In aqueous solution, the relative fluorescence intensity (RFI) of OMG was enhanced by 24% in the presence of Tween 80 at pH 3.5. The optimal conditions for the micelle enhanced fluorescence were attained by Minitab (R) program using Plackett-Burman factorial design. Pareto chart, contour plots and surface plots were used to exclude the insignificant variables and optimize the significant factors. The spectrofluorimeter was operated under synchronous mode using Lambda lambda = 30 nm and recording the RFI of the intense narrow band at 267 nm for OMG in 0.5% w/v Tween 80 + 0.2 M acetate buffer (pH 3.5) system using water as diluent. Using synchronous scan mode offered many advantages including considerable reduction of spectral overlap and enhanced linearity of the calibrators. Validation parameters were satisfied over the concentration range 0.1-2 mu g/ml. The developed method was the first analytical procedure for OMG assay in Marizev (R) tablets. Moreover, content uniformity testing and in vitro drug release of tablets were performed.
引用
收藏
页码:797 / 805
页数:9
相关论文
共 15 条